Canadian Investor Magazine | investment.opportunities.in.canadian.equities+

Reporting with Integrity

Our contributing editors choose stories based on the merit of management and

a company's potential to be a leader within its sector. read more

Learn trading techniques from the Pro's

Create wealth by learning from expert traders, brokers and investors read more

Read Canadian Investor on your iPad

Subscribe to Canadian Investor and receive access to our iPad compatible online edition. read more

Use our Custom Stock Screener

Find the stocks that interest you with our stock screener, choose from a variety of variables like intraday volume, sector, key executives or market cap. read more

Find us in the Globe & Mail

Subscribe

Discover investment opportunities in Canadian equities

Save up to 60% off the newsstand price, Pay only $19.95 for 6 issues of Canadian Investor Magazine or pay only $29.95 for two years, that's over 60% off of the newsstand price! Read it on your iPad, click here for a digital sample issue.

Availability

Where to find Canadian Investor Magazine

Canadian Investor is available at most, Chapters, Indigo, Coles, Smiths, London Drugs, Save-on-Foods, Overwaitea, Walmart and hundreds of independent magazine and bookstores across Canada.

Advertise

Reach Intelligent Readers Canada-Wide

Target highly qualified readers, Our readers are looking for investment opportunities within Canada, position your company at the forefront of these people.

Free Investor Package

Investment information from Public Companies

Access Our Stock Research Tools, Canadian Investor offers our readers and website visitors free investor packages from Canadian listed companies.
Click Here to get started.

Free Report
All you need to know about investing in stocks, futures and options.
Click Here

Research
Events and Tradeshows
StockScores Trading Plan
Stock Trading Simulation

Past Issues

News

off the wire

The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced it will hold a conference titled, Clinical Outlooks for Regenerative Medicine 2012, in partnership with Harvard Stem Cell Institute on June 19, 2012. The meeting, being held at The Starr Center, Schepens Eye Research Institute, 185 Cambridge Street, Boston, MA, will assemble a group of ~200 leading regenerative medicine executives, clinicians and investigators from major research establishments and companies to discuss how these technologies are transforming the practice of medicine.

VANCOUVER, BRITISH COLUMBIA--Functional Technologies Corp. (TSX VENTURE:FEB) is pleased to announce today recent developments and initiatives to support growing customer enthusiasm and demand for the Company's proprietary hydrogen sulphide (H2S)-preventing wine yeasts. This includes the availability of new proprietary wine yeast strains that offer low levels of both H2S and sulphur dioxide (SO2), as well as technical and marketing programs with several leading non-profit institutions and/or alliances associated with the wine industry to further expand the Company's product offerings as well as enhance the support and adoption of its wine yeasts.

VANCOUVER, BRITISH COLUMBIA--RepliCel Life Sciences Inc. is pleased to report positive results from its interim analysis of six-month post-injection data collected from its first-in-man clinical trial (TS001-2009) designed to test the safety and efficacy of the RepliCelT technology in men and women with androgenetic alopecia (pattern baldness). The primary protocol objective of the study is to assess the local (at treatment sites) safety profile of injections of autologous dermal sheath cup cells (DSCC) at six months post-injection compared to placebo. Secondary protocol objectives are to assess systemic (overall) safety and efficacy (hair growth at treatment sites) at 6 and 24 months post-injection and local safety at 24 months post-injection. The six-month interim analysis was designed to provide the Company with safety information to support the regulatory filing for a Phase IIb clinical trial.